Skip to main content
. 2022 Apr 25;14(8):3597–3606. doi: 10.18632/aging.204031

Figure 2.

Figure 2

The BET inhibitor JQ1 suppresses KRAS mutant pancreatic cancer cells. (A) The structure of the BET inhibitor JQ1. (B) Fitting curve of cytostatic responses illustrated a decreasing concentration gradient of JQ1 treated with 7 KRAS mutant pancreatic cancer cell lines (AsPC-1, MIA PaCa-2, PANC-1, HuP-T4, HuP-T3, PSN1, and CFPAC-1).